Ozempic maker cuts price of wonder drug in half in US
Patients can now get Ozempic for $US499 ($768) a month — about half of its US list price — through Novo's cash-pay pharmacy NovoCare, the company said in a statement on Monday. It's also partnering with GoodRx Holdings to offer Ozempic and its sister weight-loss drug Wegovy for the same price at pharmacies across the US.
President Donald Trump has been putting pressure on pharmaceutical companies to lower prices, including sending letters to drugmakers like Novo demanding action. The Biden administration previously attempted to get Novo to lower the price of Ozempic, the Danish company's best-selling drug, without success.
Novo said the offer is unrelated to its discussions with the US government. It comes less than a week after weight-loss rival Eli Lilly & Co. made its own adjustment, raising the list price for its obesity shot in the UK by as much as 170 per cent. Still, it's not yet clear how much difference either measure will make when it comes to variations in what patients actually pay across countries.
Novo's shares gained as much as 7.8 per cent to a session high following the announcement. The stock was already advancing on Monday after Wegovy received Food and Drug Administration approval to treat a serious form of liver disease.
The news also sent GoodRx's stock up 39 per cent, its biggest intraday jump since September 2020. GoodRx Chief Executive Officer Wendy Barnes said the partnership with Novo makes it much easier for patients to get a more affordable version of the drugs.
'We are the number one branded marketplace to seek cash pricing on brands and generics, so for that reason we already have the millions of consumers searching for these types of products,' Barnes said in an interview with Bloomberg TV. 'This is where they are looking for the most affordable price and the ability to access them.'
Novo first started selling Wegovy directly to consumers in March, following Lilly's earlier example. Both drugmakers have been contending with the widespread use of less expensive, copycat versions of their shots — known as compounded drugs — that became popular during supply shortages.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Perth Now
2 days ago
- Perth Now
Cats and dogs could get fat jabs
Weight-loss jabs could soon be administered to cats and dogs. Veterinary equivalents of drugs such as Wegovy and Mounjaro are being developed and tested by boffins and could be delivered to canines and felines via implants. Early clinical trials in cats have revealed that small doses of the drug exenatide - which works similarly to the anti-obesity medication semaglutide - are effective when it comes to reducing the calorie intake and body weight of animals. A trial last year fitted five moggies with an experimental implant known as OKV-119, which released the chemical into the animal's blood for 84 days. Analysis revealed that four of five cats had a reduction in body mass of at least five per cent. The trial is now being extended to dogs in a partnership with drug companies Okava and Vivani and the medication could be available as early as 2028 should it be successful. Michael Klotsman, the chief executive of Okava, told The Guardian newspaper: "What owners should expect to see is their pet eating appropriate portions without the previous food obsession - they'll still eat regularly and show interest in meals, just without the excess begging, scavenging or gulping behaviour."
Sky News AU
2 days ago
- Sky News AU
Australia's largest medical company CSL to cut 3,000 jobs in major restructure
Australia's largest pharmaceutical company will slash about 3,000 jobs across the globe as the company battles the global economic upheaval of Donald Trump's tariff agenda. Melbourne-headquartered CSL, a global biotechnology business specialising in bloods, vaccines and plasma products, on Tuesday revealed it will slash about 15 per cent of its staff in a sweeping restructure. In an announcement on the ASX, the company noted changing business conditions put pressure on it to restructure its operations. 'A dynamic geopolitical backdrop, competitive pressure and organisational complexity have challenged CSL and hindered its ability to deliver superior returns,' CSL said. It outlined an approach to 'driving growth, simplification and shareholder returns' which includes cost-cutting measures and merging its blood plasma and iron deficiency departments. The company also revealed it had closed 22 underperforming centres in August that represented about seven per cent of CLS's plasma footprint in the US. 'The initiatives … will result in a net headcount reduction of up to 15 per cent of CSL's employee base,' the company said. It noted the company restructure will end up impacting between about $400-$450m of cash flow in the 2026 financial year, while it will have a $100m impact in the 2027 financial year. However, the company predicts it will save about $550m annually over the next three years. CSL's chief executive Paul McKenzie lauded the company's business transformation amid market volatility impacting its operations. 'It is from this position of strength that we are taking the opportunity to make significant changes that will continue to drive shareholder returns over the long run,' Mr McKenzie told shareholders 'The transformational initiatives we are announcing today will further reshape and simplify the business, provide a platform to renew CSL's focus on our core strengths, and ultimately create even more value for our stakeholders through sustainable, profitable growth.' Alongside the restructure, CSL's influenza vaccine business, Seqirus, will be spun out of the company and become a separate entity on the ASX. As CSL revealed an array of job cuts, the pharmaceutical company also posted a 14 per cent profit jump in the 2025 financial year to USD$3.3 billion (AUD$5.1 billion). Its share price tanked, however, sinking 12.6 per cent as of 12.30pm on Tuesday and wiping about $13 billion off its market cap. The company has struggled with uncertainty after the US President earlier this month signalled he may impose massive 250 per cent tariffs on pharmaceutical imports. Trump said at the start of August he would impose a 'small' tariff on imported pharmaceutical products before hiking it to 150 per cent within 18 months and eventually to 250 per cent.
West Australian
2 days ago
- West Australian
Biotech giant CSL to cut 3000 jobs, spin off flu vaccines arm in major restructure
Biotech giant CSL is set to axe almost 3000 jobs globally as part of a major restructure and savings drive that will see its flu vaccine arm spun off into a separately listed company. CSL shares slumped 12.3 per cent to $237.77 in early trade on Tuesday after it revealed Seqirus, which makes seasonal influenza vaccines, would list on the Australian Securities Exchange before the end of the 2026 financial year. The biotech said the demerger would 'allow autonomy to set an independent strategic direction' and make the business 'more agile and efficient to manage'. It would result in a net headcount reduction of up to 15 per cent of CSL's employee base. While it employs about 30,000 staff globally, no firm number was put on the job cuts. Seqirus contributed $US2.2 billion ($3.4b) of CSL's total revenue of $US15.6b in the 12 months ended June 30. Net profit rose 17 per cent to $US3b, just above analyst estimates of $US2.97b. The biggest shake-up of the business in decades would also see its core Behring — which collects and processes blood plasma — and Vifor — which focuses on iron deficiency and nephrology — businesses combine medical and commercial functions. CSL closed 22 underperforming US plasma centres this month and will now consolidate its research and development from 11 sites into six. These initiatives would deliver cost savings of between $US500 million and $US550m progressively over the next three years. 'Our business has grown this year despite an unprecedented level of challenge and volatility in our external operating environment,' CSL chief executive Paul McKenzie said. 'It is from this position of strength that we are taking the opportunity to make significant changes that will continue to drive shareholder returns over the long run. 'The long-term outlook for CSL's therapies and vaccines remains distinctly positive, with multiple growth opportunities driven by increasing patient demand, unique competitive positions, and scalable platforms.' The nshake-up comes as US President Donald Trump threatens to slap tariffs of up to 250 per cent on pharmaceuticals, one of Australia's biggest exports to the US. Blood products such as antiserum and plasma used in medical testing and treatments made up $1.8b of this, with CSL the major player. Medicines and pharmaceutical products were the third-biggest good exported to the US in 2024, with the trade worth more than $2b that year. CSL on Tuesday said group revenue growth in the 2026 financial yeas was anticipated to be about 4 to 5 per cent stronger than last year. Net profit for this year, excluding the non-recurring restructuring cost, is expected to be in the range of about $US3.45b to $US3.55b at constant currency, representing growth over the 2025 financial year of about 7 to 10 per cent. Dr McKenzie said the guidance assumed no impact from pharmaceutical sector tariffs. 'It is our current expectation that any such policy would not impact our ability to deliver on the strategic initiatives outlined today,' he said. 'CSL has significant operations in the US and the majority of our commercial portfolio is drug-sourced from there.' CSL plans to buy back $750m of shares this financial year, the first step in a multi-year buyback.
